These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 19567679)

  • 1. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
    Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
    Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary antitumor immune response mediated by CD4+ T cells.
    Corthay A; Skovseth DK; Lundin KU; Røsjø E; Omholt H; Hofgaard PO; Haraldsen G; Bogen B
    Immunity; 2005 Mar; 22(3):371-83. PubMed ID: 15780993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
    Corthay A; Lorvik KB; Bogen B
    Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
    Dembic Z; Schenck K; Bogen B
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
    Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
    Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
    Dembic Z; Hofgaard PO; Omholt H; Bogen B
    Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
    Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
    Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
    Eck SC; Turka LA
    Cancer Res; 2001 Apr; 61(7):3077-83. PubMed ID: 11306490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J; Moyana T
    Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
    Lauritzsen GF; Bogen B
    Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
    Bogen B
    Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
    Fredriksen AB; Sandlie I; Bogen B
    Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor.
    Klein L; Trautman L; Psarras S; Schnell S; Siermann A; Liblau R; von Boehmer H; Khazaie K
    Eur J Immunol; 2003 Mar; 33(3):806-14. PubMed ID: 12616501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
    Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
    Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.